0001209191-18-019687.txt : 20180314 0001209191-18-019687.hdr.sgml : 20180314 20180314201327 ACCESSION NUMBER: 0001209191-18-019687 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180312 FILED AS OF DATE: 20180314 DATE AS OF CHANGE: 20180314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PELLETIER SAUNDRA L CENTRAL INDEX KEY: 0001251371 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36754 FILM NUMBER: 18690757 MAIL ADDRESS: STREET 1: C/O EVOFEM BIOSCIENCES, INC. STREET 2: 12400 HIGH BLUFF DRIVE, SUITE 600 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Evofem Biosciences, Inc. CENTRAL INDEX KEY: 0001618835 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208527075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE STREET 2: SUITE 600 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 550-1900 MAIL ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE STREET 2: SUITE 600 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Neothetics, Inc. DATE OF NAME CHANGE: 20140905 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-03-12 0 0001618835 Evofem Biosciences, Inc. EVFM 0001251371 PELLETIER SAUNDRA L C/O EVOFEM BIOSCIENCES, INC. 12400 HIGH BLUFF DRIVE, SUITE 600 SAN DIEGO CA 92130 1 1 0 0 Chief Executive Officer Stock option (right to buy) 7.29 2018-03-12 4 A 0 825000 0.00 A 2028-03-12 Common Stock 825000 825000 D Ms. Pelletier acquired a vested interest in 66.67% of the shares of common stock exercisable pursuant to the option effective as of March 12, 2018 (the "Vesting Start Date"). The remaining shares shall vest in a series of twelve (12) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from the Vesting Commencement Date. The option was awarded in connection with Ms. Pelletier's service as President and Chief Executive Officer. The option was granted subject to stockholder approval and will be forfeited if stockholder approval is not obtained within twelve months of the date of grant. /s/ Melanie Ruthrauff Levy, attorney-in-fact 2018-03-14